(Q38141385)

29 August 2017

Vaccines against diseases transmitted from animals to humans: a one health paradigm (English)

1 reference

29 August 2017

1

Thomas P Monath

1 reference

PubMed ID

24060567

29 August 2017

language of work or name

English

0 references

publication date

21 September 2013

1 reference

29 August 2017

1 reference

29 August 2017

31

1 reference

29 August 2017

46

1 reference

29 August 2017

5321-5338

1 reference

Host range and emerging and reemerging pathogens

29 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

The human/animal interface: emergence and resurgence of zoonotic infectious diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Research as a part of public health emergency response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

The multiple burdens of zoonotic disease and an Ecohealth approach to their assessment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

FDA Experience with Medical Countermeasures under the Animal Rule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

West Nile virus and its emergence in the United States of America

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

West Nile virus neuroinvasive disease incidence in the United States, 2002-2006.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Long-term prognosis for clinical West Nile virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

A case-control study of factors associated with development of clinical disease due to West Nile virus, Saskatchewan 2003.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-hu

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Yellow fever vector live-virus vaccines: West Nile virus vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

7 January 2021

West Nile virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Comparative Efficacies of Three Commercially Available Vaccines against West Nile Virus (WNV) in a Short-Duration Challenge Trial Involving an Equine WNV Encephalitis Model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

A live, attenuated recombinant West Nile virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Differentiation of West Nile virus-infected animals from vaccinated animals by competitive ELISA using monoclonal antibodies against non-structural protein 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

7 January 2021

Brucellosis: an overview

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

The new global map of human brucellosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Towards a Brucella vaccine for humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Clinical manifestations of human brucellosis: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Brucellosis: the case for live, attenuated vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Rough vaccines in animal brucellosis: structural and genetic basis and present status.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Estimating herd prevalence of bovine brucellosis in 46 USA states using slaughter surveillance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Vaccination strategies for managing brucellosis in Yellowstone bison.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Progress in Brucella vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Incidence of human brucellosis in a rural area in Western Greece after the implementation of a vaccination programme against animal brucellosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Invasive Escherichia coli vaccines expressing Brucella melitensis outer membrane proteins 31 or 16 or periplasmic protein BP26 confer protection in mice challenged with B. melitensis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

A combined DNA vaccine provides protective immunity against Mycobacterium bovis and Brucella abortus in cattle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Efficacy of calfhood vaccination with Brucella abortus strain RB51 in protecting bison against brucellosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Risk factors for sporadic Shiga toxin-producing Escherichia coli O157 infections in FoodNet sites, 1999-2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Escherichia coli O157 prevalence and enumeration of aerobic bacteria, Enterobacteriaceae, and Escherichia coli O157 at various steps in commercial beef processing plants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Animal- and truckload-level associations between Escherichia coli O157:H7 in feces and on hides at harvest and contamination of preevisceration beef carcasses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Use of a siderophore receptor and porin proteins-based vaccine to control the burden of Escherichia coli O157:H7 in feedlot cattle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Effects of a siderophore receptor and porin proteins-based vaccination on fecal shedding of Escherichia coli O157:H7 in experimentally inoculated cattle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

An outcomes model to evaluate risks and benefits of Escherichia coli vaccination in beef cattle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Bartonella spp. in pets and effect on human health

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

One health: the importance of companion animal vector-borne diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Mass vaccination campaign against rabies: are dogs correctly protected? The Peruvian experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Human rabies: a disease of complex neuropathogenetic mechanisms and diagnostic challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Field evaluation of a dog owner, participation-based, bait delivery system for the oral immunization of dogs against rabies in Tunisia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Field trial with oral vaccination of dogs against rabies in the Philippines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Oral vaccination of dogs with recombinant rabies virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Bug breakfast in the bulletin: One Health and Hendra virus: a collaborative approach in action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Hendra and Nipah viruses: different and dangerous

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Pteropid bats are confirmed as the reservoir hosts of henipaviruses: a comprehensive experimental study of virus transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Henipavirus: a review of laboratory animal pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Unexpected result of Hendra virus outbreaks for veterinarians, Queensland, Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Severe Rift Valley fever may present with a characteristic clinical syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Rift Valley fever virus (family Bunyaviridae, genus Phlebovirus). Isolations from Diptera collected during an inter-epizootic period in Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Prediction of a Rift Valley fever outbreak

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Breaking the chain: Rift Valley fever virus control via livestock vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

ZH501-VSVRI: Is it Still the Best Choice for Vaccination Against Rift Valley Fever in Egypt?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Use of reassortant viruses to map attenuating and temperature-sensitive mutations of the Rift Valley fever virus MP-12 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Novel approaches to develop Rift Valley fever vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Rift valley fever: recent insights into pathogenesis and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Endemic Venezuelan equine encephalitis in the Americas: hidden under the dengue umbrella

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Venezuelan encephalitis emergence mediated by a phylogenetically predicted viral mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Epidemic Venezuelan equine encephalitis in La Guajira, Colombia, 1995.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America. VEE Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Vaccines for Venezuelan equine encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Recombinant sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Protection of black-tailed prairie dogs (Cynomys ludovicianus) against plague after voluntary consumption of baits containing recombinant raccoon poxvirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Immune responses of bison to ballistic or hand vaccination with Brucella abortus strain RB51

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

A baiting system for delivery of an oral plague vaccine to black-tailed prairie dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Of ticks, mice and men: understanding the dual-host lifestyle of Lyme disease spirochaetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

The emergence of Lyme disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Vaccines against Lyme disease: What happened and what lessons can we learn?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

The cost effectiveness of vaccinating against Lyme disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Safety, efficacy, and immunogenicity of a recombinant Osp subunit canine Lyme disease vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Prevention of Lyme disease: a review of the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Correcting a public health fiasco: The need for a new vaccine against Lyme disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

An ecological approach to preventing human infection: vaccinating wild mouse reservoirs intervenes in the Lyme disease cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Oral vaccine that breaks the transmission cycle of the Lyme disease spirochete can be delivered via bait

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Reservoir targeted vaccine for lyme borreliosis induces a yearlong, neutralizing antibody response to OspA in white-footed mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Protective efficacy of an oral vaccine to reduce carriage of Borrelia burgdorferi (strain N40) in mouse and tick reservoirs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Development of a baited oral vaccine for use in reservoir-targeted strategies against Lyme disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Human Mycobacterium bovis infection in the United Kingdom: Incidence, risks, control measures and review of the zoonotic aspects of bovine tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Epidemiology of Mycobacterium bovis disease in humans, The Netherlands, 1993-2007

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Zoonotic tuberculosis due to Mycobacterium bovis in developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Classification of worldwide bovine tuberculosis risk factors in cattle: a stratified approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis--review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Risk factors associated with the prevalence of tuberculosis-like lesions in fenced wild boar and red deer in south central Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Comparing badger (Meles meles) management strategies for reducing tuberculosis incidence in cattle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Directions and issues in bovine tuberculosis epidemiology and control in New Zealand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

A new attenuated Mycobacterium bovis vaccine protects brushtail possums (Trichosurus vulpecula) against experimental tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Oral vaccination reduces the incidence of tuberculosis in free-living brushtail possums

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Lipid-formulated bcg as an oral-bait vaccine for tuberculosis: vaccine stability, efficacy, and palatability to brushtail possums (Trichosurus vulpecula) in New Zealand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

The use of commercially available vaccines for the oral vaccination of foxes against rabies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Oral vaccination of foxes against rabies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Oral immunization of foxes against rabies. Laboratory and field studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Assessing anti-rabies baiting--what happens on the ground?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Efficacy of oral vaccination in the final stage of fox rabies elimination in Switzerland.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Vaccination against rabies: construction and characterization of SAG2, a double avirulent derivative of SADBern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Vaccination of wildlife against rabies: successful use of a vectored vaccine obtained by recombinant technology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Efficacy of three oral rabies vaccine-baits in the red fox: a comparison

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

7 January 2021

Arctic rabies--a review

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Rabies challenge of captive striped skunks (Mephitis mephitis) following oral administration of a live vaccinia-vectored rabies vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Oral rabies vaccination in north america: opportunities, complexities, and challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Rabies surveillance in the United States during 2006.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Potential effect of prior raccoonpox virus infection in raccoons on vaccinia-based rabies immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Tactics and economics of wildlife oral rabies vaccination, Canada and the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Molecular inferences suggest multiple host shifts of rabies viruses from bats to mesocarnivores in Arizona during 2001-2009.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Aerial distribution of ONRAB baits as a tactic to control rabies in raccoons and striped skunks in Ontario, Canada.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

High-density baiting with ONRAB® rabies vaccine baits to control Arctic-variant rabies in striped skunks in Ontario, Canada.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Effect of irrigated rice agriculture on Japanese encephalitis, including challenges and opportunities for integrated vector management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Occurrence of Japanese encephalitis virus mosquito vectors in relation to urban pig holdings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Q Fever: current state of knowledge and perspectives of research of a neglected zoonosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

The Q fever epidemic in The Netherlands: history, onset, response and reflection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Four-year evaluation of the effect of vaccination against Coxiella burnetii on reduction of animal infection and environmental contamination in a naturally infected dairy sheep flock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

The importance of including swine and poultry workers in influenza vaccination programs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Human and animal vaccination delivery to remote nomadic families, Chad

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Emergency response to raccoon rabies introduction into Ontario

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Current Status of Veterinary Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Assembling a global vaccine development pipeline for infectious diseases in the developing world

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Human adenovirus type 5 vectors expressing rabies glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5'-noncoding region and the E2 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.029

7 January 2021

inferred from DOI database lookup

Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep.

1 reference

12 December 2020

How the research-based industry approaches vaccine development and establishes priorities.

1 reference

12 December 2020

Field Studies of an Attenuated Venezuelan Equine Encephalomyelitis Vaccine (Strain TC-83)

1 reference

12 December 2020

Descriptive epidemiology of bovine tuberculosis in michigan (1975-2010): lessons learned

1 reference

12 December 2020

The epidemiology of tuberculosis in free-ranging African buffalo (Syncerus caffer) in the Kruger National Park, South Africa

1 reference

12 December 2020

An inactivated rift valley fever vaccine

1 reference

12 December 2020

Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle

1 reference

12 December 2020

Disorder of spermatogenesis and viral discharge into semen in boars infected with Japanese encephalitis virus (author's transl)

1 reference

12 December 2020

Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes

1 reference

12 December 2020

Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine

1 reference

12 December 2020

The oral rabies immunization of foxes and dogs with sausage baits

1 reference

12 December 2020

Active and passive immunization against Rift Valley fever virus infection in Syrian hamsters

1 reference

12 December 2020

Human health benefits from livestock vaccination for brucellosis: case study.

1 reference

12 December 2020

Safety and efficacy of an attenuated Venezuelan equine encephalomyelitis vaccine for use in Equidae

1 reference

12 December 2020

Re-evaluating the burden of rabies in Africa and Asia.

1 reference

12 December 2020

Vaccination against Lyme disease: past, present, and future

1 reference

12 December 2020

Vaccine prophylaxis of Q fever. A follow-up study of the efficacy of Q-Vax (CSL) 1985-1990.

1 reference

12 December 2020

Epidemiology of west nile in europe and in the mediterranean basin

1 reference

12 December 2020

Henipaviruses: emerging paramyxoviruses associated with fruit bats.

1 reference

12 December 2020

Immunization of burros with living Venezuelan equine encephalomyelitis virus

1 reference

12 December 2020

Hendra vaccine success announced

1 reference

12 December 2020

The use of veterinary vaccines for prevention and control of Rift Valley fever: memorandum from a WHO/FAO meeting

1 reference

12 December 2020

PPARgamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease

1 reference

12 December 2020

The safety test for poliomyelitis vaccine. I. An evaluation of variable factors in the monkey and cell culture systems

1 reference

12 December 2020

Executive summary of the AVMA One Health Initiative Task Force report

1 reference

12 December 2020

Avian influenza vaccines: a practical review in relation to their application in the field with a focus on the Asian experience

1 reference

12 December 2020

10.1016/J.VACCINE.2013.09.029

Identifiers

DOI

1 reference

29 August 2017

0 references

1 reference

PubMed ID

24060567